Killer immunoglobulin‐like receptor genotypes and chronic myeloid leukemia outcomes after imatinib cessation for treatment‐free remission
Abstract Background Natural Killer (NK) cells are innate lymphoid cells that can be cytotoxic toward a large panel of solid tumors and hematological malignancies including chronic myeloid leukemia (CML). Such a cytotoxicity depends on various receptors. Killer immunoglobulin‐like receptors (KIR) bel...
| Main Authors: | , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2019-09-01
|
| Series: | Cancer Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/cam4.2371 |
| _version_ | 1818941086710628352 |
|---|---|
| author | Pierre‐Yves Dumas Emilie Bérard Claire Bréal Stéphanie Dulucq Delphine Réa Franck Nicolini Edouard Forcade Melody Dufossée Jean‐Max Pasquet Béatrice Turcq Audrey Bidet Noel Milpied Julie Déchanet‐Merville Xavier Lafarge Gabriel Etienne François‐Xavier Mahon French Intergroup in Chronic Myeloid Leukemia |
| author_facet | Pierre‐Yves Dumas Emilie Bérard Claire Bréal Stéphanie Dulucq Delphine Réa Franck Nicolini Edouard Forcade Melody Dufossée Jean‐Max Pasquet Béatrice Turcq Audrey Bidet Noel Milpied Julie Déchanet‐Merville Xavier Lafarge Gabriel Etienne François‐Xavier Mahon French Intergroup in Chronic Myeloid Leukemia |
| author_sort | Pierre‐Yves Dumas |
| collection | DOAJ |
| description | Abstract Background Natural Killer (NK) cells are innate lymphoid cells that can be cytotoxic toward a large panel of solid tumors and hematological malignancies including chronic myeloid leukemia (CML). Such a cytotoxicity depends on various receptors. Killer immunoglobulin‐like receptors (KIR) belong to these receptors and are involved in maturation process, then in the activation abilities of NK cells. Methods: We investigated the prognostic impact of the KIR2DL5B genotype in 240 CML patients included in two clinical trials investigating tyrosine kinase inhibitors (TKI) discontinuation: STIM and STIM2. Results: After adjustment for standard risk factors in CML, we found that the inhibitory receptor KIR2DL5B‐positive genotype was independently related to a delayed second deep molecular remission (HR 0.54, 95% CI [0.32‐0.91], P = 0.02) after TKI rechallenge but not to time to first deep molecular remission or treatment‐free remission rates. Conclusion: These results suggest that KIR2DL5B could carry a role in lymphocyte‐mediated control of leukemic residual disease control in patient with CML relapse. |
| first_indexed | 2024-12-20T06:49:57Z |
| format | Article |
| id | doaj.art-fde024de99b941a08e4dd670a8681016 |
| institution | Directory Open Access Journal |
| issn | 2045-7634 |
| language | English |
| last_indexed | 2024-12-20T06:49:57Z |
| publishDate | 2019-09-01 |
| publisher | Wiley |
| record_format | Article |
| series | Cancer Medicine |
| spelling | doaj.art-fde024de99b941a08e4dd670a86810162022-12-21T19:49:35ZengWileyCancer Medicine2045-76342019-09-018114976498510.1002/cam4.2371Killer immunoglobulin‐like receptor genotypes and chronic myeloid leukemia outcomes after imatinib cessation for treatment‐free remissionPierre‐Yves Dumas0Emilie Bérard1Claire Bréal2Stéphanie Dulucq3Delphine Réa4Franck Nicolini5Edouard Forcade6Melody Dufossée7Jean‐Max Pasquet8Béatrice Turcq9Audrey Bidet10Noel Milpied11Julie Déchanet‐Merville12Xavier Lafarge13Gabriel Etienne14François‐Xavier Mahon15French Intergroup in Chronic Myeloid LeukemiaService d'Hématologie Clinique et Thérapie Cellulaire CHU Bordeaux F-33000 Bordeaux FranceService d'Epidémiologie Centre Hospitalier Universitaire de Toulouse Toulouse FranceService d'Hématologie Clinique et Thérapie Cellulaire CHU Bordeaux F-33000 Bordeaux FranceLaboratoire d'Hématologie CHU Bordeaux F-33000 Bordeaux FranceService d'Hématologie Hôpital Saint Louis Paris FranceService d'Hématologie and INSERM U590 CRCL, Centre Léon Bérard Lyon FranceService d'Hématologie Clinique et Thérapie Cellulaire CHU Bordeaux F-33000 Bordeaux FranceInstitut National de la Santé et de la Recherche Médicale INSERM U1035 Bordeaux FranceInstitut National de la Santé et de la Recherche Médicale INSERM U1035 Bordeaux FranceInstitut National de la Santé et de la Recherche Médicale INSERM U1218 Bordeaux FranceLaboratoire d'Hématologie CHU Bordeaux F-33000 Bordeaux FranceService d'Hématologie Clinique et Thérapie Cellulaire CHU Bordeaux F-33000 Bordeaux FranceCentre National de la Recherche Scientifique, ImmunoConcEpT, UMR 5164 Bordeaux FranceInstitut National de la Santé et de la Recherche Médicale INSERM U1035 Bordeaux FranceInstitut National de la Santé et de la Recherche Médicale INSERM U1218 Bordeaux FranceInstitut National de la Santé et de la Recherche Médicale INSERM U1218 Bordeaux FranceAbstract Background Natural Killer (NK) cells are innate lymphoid cells that can be cytotoxic toward a large panel of solid tumors and hematological malignancies including chronic myeloid leukemia (CML). Such a cytotoxicity depends on various receptors. Killer immunoglobulin‐like receptors (KIR) belong to these receptors and are involved in maturation process, then in the activation abilities of NK cells. Methods: We investigated the prognostic impact of the KIR2DL5B genotype in 240 CML patients included in two clinical trials investigating tyrosine kinase inhibitors (TKI) discontinuation: STIM and STIM2. Results: After adjustment for standard risk factors in CML, we found that the inhibitory receptor KIR2DL5B‐positive genotype was independently related to a delayed second deep molecular remission (HR 0.54, 95% CI [0.32‐0.91], P = 0.02) after TKI rechallenge but not to time to first deep molecular remission or treatment‐free remission rates. Conclusion: These results suggest that KIR2DL5B could carry a role in lymphocyte‐mediated control of leukemic residual disease control in patient with CML relapse.https://doi.org/10.1002/cam4.2371chronic myeloid leukemiaimatinibkiller immunoglobulin‐like receptorsnatural killertreatment‐free remission |
| spellingShingle | Pierre‐Yves Dumas Emilie Bérard Claire Bréal Stéphanie Dulucq Delphine Réa Franck Nicolini Edouard Forcade Melody Dufossée Jean‐Max Pasquet Béatrice Turcq Audrey Bidet Noel Milpied Julie Déchanet‐Merville Xavier Lafarge Gabriel Etienne François‐Xavier Mahon French Intergroup in Chronic Myeloid Leukemia Killer immunoglobulin‐like receptor genotypes and chronic myeloid leukemia outcomes after imatinib cessation for treatment‐free remission Cancer Medicine chronic myeloid leukemia imatinib killer immunoglobulin‐like receptors natural killer treatment‐free remission |
| title | Killer immunoglobulin‐like receptor genotypes and chronic myeloid leukemia outcomes after imatinib cessation for treatment‐free remission |
| title_full | Killer immunoglobulin‐like receptor genotypes and chronic myeloid leukemia outcomes after imatinib cessation for treatment‐free remission |
| title_fullStr | Killer immunoglobulin‐like receptor genotypes and chronic myeloid leukemia outcomes after imatinib cessation for treatment‐free remission |
| title_full_unstemmed | Killer immunoglobulin‐like receptor genotypes and chronic myeloid leukemia outcomes after imatinib cessation for treatment‐free remission |
| title_short | Killer immunoglobulin‐like receptor genotypes and chronic myeloid leukemia outcomes after imatinib cessation for treatment‐free remission |
| title_sort | killer immunoglobulin like receptor genotypes and chronic myeloid leukemia outcomes after imatinib cessation for treatment free remission |
| topic | chronic myeloid leukemia imatinib killer immunoglobulin‐like receptors natural killer treatment‐free remission |
| url | https://doi.org/10.1002/cam4.2371 |
| work_keys_str_mv | AT pierreyvesdumas killerimmunoglobulinlikereceptorgenotypesandchronicmyeloidleukemiaoutcomesafterimatinibcessationfortreatmentfreeremission AT emilieberard killerimmunoglobulinlikereceptorgenotypesandchronicmyeloidleukemiaoutcomesafterimatinibcessationfortreatmentfreeremission AT clairebreal killerimmunoglobulinlikereceptorgenotypesandchronicmyeloidleukemiaoutcomesafterimatinibcessationfortreatmentfreeremission AT stephaniedulucq killerimmunoglobulinlikereceptorgenotypesandchronicmyeloidleukemiaoutcomesafterimatinibcessationfortreatmentfreeremission AT delphinerea killerimmunoglobulinlikereceptorgenotypesandchronicmyeloidleukemiaoutcomesafterimatinibcessationfortreatmentfreeremission AT francknicolini killerimmunoglobulinlikereceptorgenotypesandchronicmyeloidleukemiaoutcomesafterimatinibcessationfortreatmentfreeremission AT edouardforcade killerimmunoglobulinlikereceptorgenotypesandchronicmyeloidleukemiaoutcomesafterimatinibcessationfortreatmentfreeremission AT melodydufossee killerimmunoglobulinlikereceptorgenotypesandchronicmyeloidleukemiaoutcomesafterimatinibcessationfortreatmentfreeremission AT jeanmaxpasquet killerimmunoglobulinlikereceptorgenotypesandchronicmyeloidleukemiaoutcomesafterimatinibcessationfortreatmentfreeremission AT beatriceturcq killerimmunoglobulinlikereceptorgenotypesandchronicmyeloidleukemiaoutcomesafterimatinibcessationfortreatmentfreeremission AT audreybidet killerimmunoglobulinlikereceptorgenotypesandchronicmyeloidleukemiaoutcomesafterimatinibcessationfortreatmentfreeremission AT noelmilpied killerimmunoglobulinlikereceptorgenotypesandchronicmyeloidleukemiaoutcomesafterimatinibcessationfortreatmentfreeremission AT juliedechanetmerville killerimmunoglobulinlikereceptorgenotypesandchronicmyeloidleukemiaoutcomesafterimatinibcessationfortreatmentfreeremission AT xavierlafarge killerimmunoglobulinlikereceptorgenotypesandchronicmyeloidleukemiaoutcomesafterimatinibcessationfortreatmentfreeremission AT gabrieletienne killerimmunoglobulinlikereceptorgenotypesandchronicmyeloidleukemiaoutcomesafterimatinibcessationfortreatmentfreeremission AT francoisxaviermahon killerimmunoglobulinlikereceptorgenotypesandchronicmyeloidleukemiaoutcomesafterimatinibcessationfortreatmentfreeremission AT frenchintergroupinchronicmyeloidleukemia killerimmunoglobulinlikereceptorgenotypesandchronicmyeloidleukemiaoutcomesafterimatinibcessationfortreatmentfreeremission |